Skip to main content

Table 2 Potential targets for breast cancer precise therapy

From: Cancer-associated adipocytes: key players in breast cancer progression

Agent

Target

In vitro effect

Preclinical and clinical effects

References

Cenicriviroc

CCR2

Inhibitor of CCR2

Inhibition of monocyte recruitment, Prevent virus from entering into a human cell

[137, 138]

Maraviroc

CCR5

Inhibitor of CCR5

Blockade the HIV from entering macrophages and T cells

[139]

Tocilizumab

IL-6R

Monoclonal antibody against IL-6R

Hindering IL-6 from exerting its pro-inflammatory effects.

[140]

Canakinumab

IL-1β

Monoclonal antibody against IL-1β

Treatment of cryopyrin-associated periodic syndromes

[141]

Infliximab

TNF-α

Monoclonal antibody against TNF-α

Treatment of autoimmune diseases

[142,143,144]

Bevacizumab (Avastin)

VEGF

Monoclonal antibody against VEGF-A

Angiogenesis inhibitor

[145]

AZD3695

MCT1

MCT1 inhibition

Reduce tumor growth, Increase intra-tumor lactate

[146]

Nivolumab

PD-1

Monoclonal antibody against PD-1

Checkpoint inhibitor

[147]

Durvalumab

PD-L1

Monoclonal antibody against PD-L1

Blocking the interaction of PD-L1 with the PD-1 and CD80 (B7.1) molecules.

[148]

Avelumab

PD-L1

Monoclonal antibody against PD-L1

Blocking the interaction of PD-L1 binding to PD-1

[149]